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1 INTRODUCTION AND OBJECTIVES 
 
 
Since 1982 genetically modified mice have been widely employed in the biological and 
medical research in order to investigate different human and animal diseases and also to 
test possible therapies. Recently, transgenic animal models have also been generated to 
develop new treatment options in diabetes mellitus. The transgenic technology has been 
used for targeting molecules like hormones (Cayrol et al. 2006), oncogenes (Pelengaris 
et al. 2002), growth factors (Garcia-Ocana et al. 2001) or transcription factors (Ahlgren 
et al. 1998) in the pancreatic islets. Thereby, the rat (Hanahan 1985; Vasavada et al. 
1996), mouse (Hara et al. 2003) and human (Hotta et al. 1998; Krakowski et al. 1999) 
insulin promoters have been employed to control the overexpression of the transgene in 
the pancreatic β-cells. However, a big drawback of the most frequently recommended 
rat insulin promoter is the detected expression of the transgene not only in β-cells but 
also in several areas of the brain (Gannon et al. 2000; Martin et al. 2003). 
 
The use of mice as animal models is still useful for studies investigating basic problems 
of β-cell physiology. However, researches regarding, for instance, islet 
xenotransplantation approaches require large animal models. Due to similarities to 
humans in the blood glucose level regulation and in the general physiology, pigs are 
excellent candidates for such studies. Furthermore, results of different studies support 
the possibility to obtain pancreatic islets from newborn and adult pigs for 
xenotransplantation (MacKenzie et al. 2003; Cardona et al. 2006; Hering et al. 2006). 
Therefore, there is a considerable interest in the development of tools for the genetic 
modifications of porcine pancreatic islets for the delivery of gene products direct to 
β-cells. 
 
The aim of the present study was to create an expression cassette for the β-cell-specific 
overexpression of transgenes under the control of the porcine insulin promoter. 
The functionality of the construct was verified by expressing human betacellulin, a 
ligand of the EGFR family, known for its ability to stimulate β-cell differentiation in 
vitro and in transgenic mouse model. 
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2 LITERATURE REVIEW 
 
 
2.1 The Epidermal Growth Factor Receptor system 
 
2.1.1 Epidermal Growth Factor Receptor 
 
The epidermal growth factor receptor (EGFR) family of tyrosine kinase receptors 
comprises the following members: ErbB1/EGFR/HER1, ErbB2/Neu/HER2, 
ErbB3/HER3 and ErbB4/HER4 (Figure A). 
Studies on the structure of EGF receptors revealed the presence of several common 
regions, including an extracellular ligand-binding region, a single membrane-spanning 
region and a cytoplasmic part with a tyrosine kinase-containing domain (Holbro & 
Hynes 2004). 
 
 
 
ErbB1 ErbB2 ErbB3 ErbB4
 
Figure A     Epidermal Growth Factor Receptor and the related ErbB2-4 receptors. 
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The EGFR and many of its ligands are broadly expressed in the gastrointestinal tract, 
including the pancreas (Miettinen & Heikinheimo 1992). In the adult pancreas, the EGF 
receptor is predominantly expressed in the islets of Langerhans and ductal epithelial 
cells (Ueda et al. 2004). The expression of ErbB2 in the developing mouse pancreas 
has been detected in the ducts (Kritzik et al. 2000), as well as in the proliferating 
human adult duct cells (Rescan et al. 2005). ErbB3 is expressed in the developing 
mouse pancreatic ducts (Kritzik et al. 2000) and mesenchyme surrounding the pancreas 
(Erickson et al. 1997). The ErbB4 protein has been detected in the mouse pancreas as 
early as embryonic (E) day 12.5 (Huotari et al. 2002) and it is expressed in the fetal 
mouse pancreatic ducts (Kritzik et al. 2000). In the proliferating human adult pancreatic 
duct cells ErbB4 is expressed only weakly (Rescan et al. 2005). 
Moreover, the presence of the ErbB receptors has been shown also in other tissues like 
peripheral nervous system (Woldeyesus et al. 1999), heart (Gassmann et al. 1995; Lee 
et al. 1995), and several epithelial organs (Miettinen et al. 1995; Sibilia et al. 1998). 
 
The activation of ErbB receptors initiates a rich network of signaling pathways, 
culminating in variety of responses ranging from cell division to death. The 
phosphorylated residues are recognized as docking sites by different signal molecules, 
which activation promotes intracellular signaling cascades and control variety of 
genetic processes. Additionally, the activation of ErbBs occurs not only through ligand 
binging, but also via heterologous signals, like hormones, neurotransmitters, 
lymphokines and stress inducers (Carpenter 1999). However, two of the ErbB receptors 
make an exception to this rule. The “ligandless” ErbB2 receptor requires 
heterodimerisation with another ErbB receptor to be activated (Klapper et al. 1999). 
Also the ErbB3 receptor needs a dimerisation with a second ErbB receptor to become 
phosphorylated and to initiate signalling pathways (Guy et al. 1994). Therefore, neither 
ErbB2 nor ErbB3 in isolation can perform its function as membrane receptor. The most 
important downstream signaling pathways of ErbB receptors (Figure B) are the Ras- 
and Shc-activated MAPK networks, as well as phosphoinositide 3-kinase (PI3K)-
activated pathway (Yarden & Sliwkowski 2001). 
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Figure B  The EGFR system: Binding of a ligand (1) permits the receptor dimerisation and 
activation (2) of downstream signaling pathways, (3a and 3b) changing the 
activity of multiple nuclear transcription factors and cellular transcriptional 
program (4). 
 
 
The biological role of the ErbB receptors and their ligands has been often studied by 
using genetically modified mouse models. The epidermal growth factor receptor 
(EGFR)-deficient mice exhibited a significant reduction of the pancreas weight and 
disturbed pancreas morphogenesis (Miettinen et al. 2000). These alterations have been 
suggested to result from the impaired branching of the ductal tree. Although EGFR 
activation was reduced by only 40%, the transgenic mice exhibited a significant 
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decreased β-cell mass and became diabetic within two weeks of birth. To study the role 
of the EGF receptor in adult pancreas, a mouse model expressing a kinase-deficient and 
dominant-negative EGFR under the control of Pdx1 (pancreatic duodenal homeobox 
factor-1) promoter was generated (Miettinen et al. 2006). These mice showed an 
impaired postnatal β-cell growth, resulting in diabetes (Miettinen et al. 2006). 
 
Moreover, the other ErbB receptors are probably also required for an appropriate 
function of the pancreas. Knockout mouse models for ErbB2-, ErbB3- and ErbB4 
exhibited early prenatal mortality, mostly before pancreatic organogenesis could take 
place (Gassmann et al. 1995; Lee et al. 1995; Erickson et al. 1997). 
 
ErbB receptors have been shown to play an important role in the development and 
functionality of many other organs. For instance, EGFR knockout mice revealed the 
necessity of this receptor for the proper craniofacial development (Miettinen et al. 
1995). In this study, the heterozygous Egfr+/- mice exhibited a normal weight and 
reproductive ability, while Egfr-/- animals survived only a few days after birth because 
of lethal defects in the respiratory system and epithelial immaturity in several organs. 
Additionally, absence of a functioning EGFR in these mice led to abnormalities in the 
epidermis and hair coat. The skin was thinner and almost transparent, with only few 
hair follicles (Miettinen et al. 1995). Other studies on mice lacking the Egfr gene also 
demonstrated alterations in skin, kidney, brain, liver and gastrointestinal tract 
(Miettinen et al. 1995; Sibilia & Wagner 1995; Threadgill et al. 1995). 
 
Numerous studies demonstrated that alterations of ErbB receptor activity were 
associated with the appearance of severe cancer types including carcinomas of the 
breast (Slamon et al. 1987; Slamon et al. 1989; Barnes et al. 1992; Prenzel et al. 1999; 
Gschwind et al. 2002), colon and rectum (Shirai et al. 1995; Yang et al. 1997), 
endometrium (Berchuck et al. 1991), lung (Brandt-Rauf et al. 1994), ovary (Tanner et 
al. 1996) and prostate gland (Zhau et al. 1992; Fox et al. 1994). Abnormalities in the 
ErbB pathway system are often the reason for initiation and progression of cancer. 
Overproduction of ligands, overexpression of receptors or constitutive activation of 
receptors can drive the cell to uncontrolled proliferation. One of the best characterized 
ErbB ligands connected with human cancers is TGFA (transforming growth factor-
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alpha). Overexpression of TGFA and EGFR, particularly in lung, ovary and colon 
tumors, predicts poor recovery chances (Sandgren et al. 1990; Salomon et al. 1995). 
Overexpression of ErbB2 is often associated with the invasive ductal breast cancers 
(Slamon et al. 1987; Slamon et al. 1989), however alterations in ErbB2 alone are 
insufficient for breast cancer progression (Ross & Fletcher 1999). Importantly, the 
heterodimers ErbB2/ErbB3 represent an extremely high mitogenic complex (Pinkas-
Kramarski et al. 1998). Nevertheless, it has been shown that down-regulation of ErbB2 
follows decrease of ErbB3 expression as well (Lane et al. 2000; Neve et al. 2000; 
Basso et al. 2002; Motoyama et al. 2002). This observation suggests a close connection 
between these two partners in the initiation of signaling pathways and cell proliferation. 
 
2.1.2 Ligands of the Epidermal Growth Factor Receptor family 
 
There are seven known EGFR ligands: epidermal growth factor (EGF), transforming 
growth factor-alpha (TGFA), amphiregulin (AREG), heparin-binding EGF-like growth 
factor (HB-EGF), betacellulin (BTC), epiregulin (EREG) and epigen (EPGN) (Harris et 
al. 2003; Schneider & Wolf 2009). The genes encoding four of these ligands, EREG, 
EPGN, AREG and BTC are loated on the same chromosome in mice and humans 
(chromosomes 5 and 4, respectively) (Pathak et al. 1995). This tight linkage suggests 
that they may have arisen through a tandem gene duplication event. In general, the 
overall organization of the genes encoding members of the EGF family is highly 
conserved. These genes consist of 6 exons, where the first one encodes the 5’UTR and 
signal peptide. Exon 2 encodes the N-terminal precursor. The third exon encodes the 
mature EGF with the two first disulfide loops and the fourth accounts for expression of 
the third loop of the EGF-like domain. Exon 5 encodes the cytoplasmic region and exon 
6 the 3’UTR (Harris et al. 2003). 
 
The ligands of the EGFR family are synthesized as type I transmembrane proteins 
consisting of an N-terminal part, EGF motif, a short juxtamembrane stalk and a 
carboxy-terminal domain. The EGF motif contains 40 amino acids with six cysteines 
arranged as three disulfide bridges and forming three loops (Harris et al. 2003; 
Schneider & Wolf 2009;). An amino acid between the second and the third loop is 
called “hinge residue”. The probable function of this structure is to simplify the 
movement of these two structures (van Zoelen et al. 2000). 
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Cleavage of the EGFR ligands by surface proteases allows releasing the mature ligands 
from the cell membrane and their activity as growth factors (Massague & Pandiella 
1993). 
 
2.1.2.1 Amphiregulin (AREG) 
 
AREG was identified in the human breast adenocarcinoma cell line, MCF-7 (Shoyab et 
al. 1988). This growth factor is expressed in many tissues, including placenta, ovary, 
testis, heart, pancreas, spleen, kidney, lung, ovary, colon and breast (Plowman et al. 
1990). Under normal conditions, amphiregulin is not expressed in the liver. 
Nevertheless some studies demonstrated an upregulated AREG gene expression after 
liver injury or partial hepatectomy (Berasain et al. 2005; Castillo et al. 2006; Fausto et 
al. 2006). Amphiregulin activation appears to have an important functional role in the 
development and maturation of different organs, including mammary gland (Kenney et 
al. 1996; Sternlicht et al. 2005), bones (Qin et al. 2005) or placenta (Fukami et al. 
2009). Due to its ability to inhibit the growth of many human tumors and to stimulate 
the proliferation of other cells, like fibroblasts, keratinocytes or epithelial cells, AREG 
is known as a bifunctional growth factor (Plowman et al. 1990; Cook et al. 1991; 
Normanno et al. 1994; Chu et al. 2005). 
 
Reduced expression of AREG was detected in prolactin receptor knockout mice 
(Ormandy et al. 2003). Also, female AREG-deficient mice exhibited a defective 
mammary gland development and inadequate quality or quantity of milk (Luetteke et 
al. 1999). Together, these findings indicate that amphiregulin might be regulated by 
prolactin during the pregnancy and is necessary for an appropriate growth of mammary 
tissue. 
 
Amphiregulin seems to have an effect on other organs as well. For instance, 
overexpression of AREG in mouse pancreas caused an increased proliferation of 
pancreatic duct cells (Wagner et al. 2002). Results of such investigations suggested that 
amphiregulin induces a mitogenic response in pancreatic duct cells through activation 
of Ras, CDK2 or CDK4 (Wagner et al. 2002). Moreover, studies on human pancreatic 
cancer cell lines indicated an elevated expression of amphiregulin in the cytoplasm of 
these cells being a signal of a more advanced clinical stage of the disease. These 
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findings suggested the contribution of AREG to aberrant activation of EGF receptor in 
pancreatic tumor cells (Ebert et al. 1994). 
 
2.1.2.2 Epidermal Growth Factor (EGF) 
 
EGF was originally detected in the mouse submaxillary gland (Cohen 1962). This 
ligand is known for its ability to stimulate precocious tooth eruption and eyelid opening 
in newborn mice (Cohen 1962), skin development in fetal lambs (Wynn et al. 1995) 
and lung maturation in fetal rabbits (Catterton et al. 1979). Moreover, EGF has been 
shown to have several functions in the bone cells such as stimulation of the osteoblast 
proliferation (Ng et al. 1983) or inhibition of collagen production (Hata et al. 1984). 
 
Transgenic mice overexpressing EGF under the control of the human insulin promoter 
exhibited significant morphological changes within their pancreata (Krakowski et al. 
1999). The pancreatic islets of these animals were larger than the islets of their non-
transgenic littermates. Furthermore, a significant fibrosis around the islets was observed 
in the pancreas of transgenic animals. Treatment with EGF has been shown to stimulate 
the human adult pancreatic duct cells to expand and transdifferentiate (Rescan et al. 
2005). Adult human duct cells employed for this study exhibited an increased activation 
of ErbB1 and ErbB2 receptors, followed by elevated proliferation of a particular 
fraction of the pancreatic duct cells. The authors (Rescan et al. 2005) suggested a 
possible role of EGF in converting pancreatic duct cells into insulin producing cells in 
diabetic patients. Moreover, EGF has been postulated to stimulate β-cell differentiation 
and islet neogenesis regulation during the pancreas development (Yasuda et al. 2007). 
EGF has been also shown to have a positive effect on glucose metabolism in diabetic 
animals (Suarez-Pinzon & Rabinovitch 2008; Lim et al. 2009) increasing the insulin 
secretion and reducing the glucose levels. However, some other studies did not support 
this theory, postulating that EGF was not able to modulate the plasma insulin content 
after glucose administration (Jansen et al. 2006). 
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2.1.2.3 Epigen (EPGN) 
 
Epigen, a novel member of the EGFR family, was first described in mouse 
keratinocytes (Strachan et al. 2001). EPGN has a restricted tissue distribution; it is 
present in heart, liver and testis (Strachan et al. 2001). Moreover, EPGN is expressed in 
the inner and outer root sheath of hair follicles in newborn mouse skin (Kochupurakkal 
et al. 2005). So far, the function of epigen in the pancreas has not been investigated. 
 
In the epithelial cells, epigen stimulates the phosphorylation of the EGFR and MAPK 
kinase proteins (Strachan et al. 2001). Although the binding affinity of EPGN to 
receptor is 100-fold lower than receptor binding affinity of EGF, its mitogenic potency 
is significantly higher (Kochupurakkal et al. 2005). These authors suggested that the 
low affinity of the ligand to the receptor may elicit such a potent response because of 
ineffective internalization and recycling of the ligand-receptor complex. 
 
Recently, a transgenic mouse model with ubiquitously expression of epigen has been 
generated by Dahlhoff and colleagues (Dahlhoff et al. 2009). The transgenic mice were 
characterized by visibly reduced body size and impaired development of the first coat. 
Histological examination revealed extraordinarily enlarged sebaceous glands in the skin 
of EPGN-transgenic mice, suggesting a function of the EGFR pathways in the 
proliferation and/or differentiation of sebocytes. 
 
2.1.2.4 Epiregulin (EREG) 
 
Epiregulin was identified as a growth inhibitory factor from the conditioned medium of 
the fibroblast tumor cell line NIH-3T3 (Toyoda et al. 1995). This protein consists of 46 
amino-acid residues and exhibits a dual biological activity, resembling in this regard 
AREG. On the one hand, it stimulates the proliferation of fibroblasts, hepatocytes, 
smooth muscle cells and keratinocytes (Shirakata et al. 2000; Takahashi et al. 2003). 
On the other hand, it inhibits the growth of several tumor-derived epithelial cell lines 
(Lee et al. 2004). EREG was found to be an autocrine growth factor in relatively low 
levels in the human keratinocytes and in tissue-resident macrophages (Shirasawa et al. 
2004). Mice lacking epiregulin showed chronic dermatitis in the ear, face and neck area 
(Shirasawa et al. 2004). The authors demonstrated that epiregulin is a crucial molecule 
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for the regulation of IL-18 mRNA expression in keratinocytes. In contrast, Lee et al. 
reported that an independent line of EREG knockout mice did not display any abnormal 
phenotype (Lee et al. 2004) postulating that loss of epiregulin could be compensated by 
other EGFR ligands. Epiregulin as appears also to be an important factor in the female 
reproduction (Park et al. 2004) and liver regeneration (Toyoda et al. 1995). 
Investigations using insulinoma cell lines suggested that epiregulin may be a growth 
and insulinotropic factor in pancreatic β-cells (Kuntz et al. 2005). Treatment of rat 
insulinoma cell lines with epiregulin resulted in increased proliferation of these cells 
and elevated insulin production (Kuntz et al. 2005). 
Interestingly, overexpression of epiregulin is often correlated with pancreas and 
prostate cancer development (Torring et al. 2000; Zhu et al. 2000). 
 
2.1.2.5 Heparin-binding EGF-like growth factor (HBEGF) 
 
HB-EGF was first described as a heparin binding mitogen in fibroblasts and smooth 
muscle cells (Besner et al. 1990; Higashiyama et al. 1991). HB-EGF is also present in 
the wound fluid, skin, lung and heart (Vaughan et al. 1992a; Vaughan et al. 1992b). 
The presence of HB-EGF have been confirmed both in the normal islets of Langerhans 
(Kaneto et al. 1997) and in the pancreatic cancer cells (Kobrin et al. 1994). Moreover, 
presence of HB-EGF in the duct cells of fetal and neonatal rat pancreas suggests a 
possible involvement of this protein in pancreas development (Kaneto et al. 1997). 
 
Regenerative and therapeutic effects of HB-EGF on pancreatic β-cells have been 
postulated by Kozawa et al. using a diabetic mouse model (Kozawa et al. 2005). 
Results of this study demonstrated that treatment of a diabetic mouse with HB-EGF 
stimulated proliferation and differentiation of pre-existing β-cells leading to an increase 
in β-cell mass and improvement of glucose metabolism. However, overexpression of 
this growth factor in pancreas has been shown to promote pancreas cancer (Ito et al. 
2001; Hurtado et al. 2007), fibrosis and epithelial metaplasia (Means et al. 2003). 
 
HB-EGF was detected also in the epithelial cells of hair follicle (Rittie et al. 2007). 
Furthermore, its expression in the advancing epithelial margin and islands of 
regenerating epithelium within burn wounds suggests a role for this protein in wound 
healing (Marikovsky et al. 1993). Deletion of the HB-EGF gene resulted in early 
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postnatal mortality because of defected cardiac chamber dilation and heart valve 
malformation (Yamazaki et al. 2003), hypetrophic cardiomiocytes and hypoplastic lung 
(Iwamoto et al. 1999; Jackson et al. 2003). It is the only EGFR ligand whose deficiency 
causes early postnatal mortality. Loss of this ligand has been connected with epidermal 
hyperplasia and impaired differentiation of keratinocytes. For instance, keratinocyte-
specific HB-EGF-deficient mice were characterized by decreased wound closure ability 
(Shirakata et al. 2005). 
 
2.1.2.6 Transforming-Growth-Factor-α (TGFA) 
 
TGFA was initially identified in medium conditioned by retrovirus transformed rodent 
cells (Ozanne et al. 1980; Twardzik et al. 1982; Marquardt et al. 1983). This growth 
factor is also expressed in epidermis and hair follicle. Moreover, TGFA mRNA has 
been detected in the preimplantation mouse embryos (Rappolee et al. 1988), in the 
anterior pituitary (Samsoondar et al. 1986), skin keratinocytes (Coffey, Jr. et al. 1987) 
and brain (Wilcox & Derynck 1988). Also, presence of the TGFA in the fetal and 
neonatal upper digestive tract and pancreas suggests a possible functional role of this 
protein in the growth and development of these organs (Hormi et al. 1995). 
 
Overexpression of TGFA under control of the elastase promoter in transgenic mice has 
been shown to cause serious alterations in the growth and differentiation of several 
adult organs (Sandgren et al. 1990). In these animals the relative weight of the 
coagulation gland, colon, small intestine, liver and pancreas was increased by up to 
3-fold. However, the average body weight of transgenic mice was significantly 
decreased. Despite these changes, there was no evidence for endocrine pancreatic 
dysfunction. Wagner et al. reported that ubiquitous TGFA overexpression in mouse 
pancreas caused the development of cancer similar to the human disease (Wagner et al. 
2002). Mitogenic properties of TGFA have been shown in different studies using a 
transgenic mouse model with overexpression of this growth factor. For instance, 
Jhappan et al. demonstrated liver neoplasia and abnormal development of pancreas in 
TGFA transgenic mice (Jhappan et al. 1990). Also, Sandgren et al. presented the 
upregulated TGFA as an impotrant factor enhancing growth and development of 
pancreas and liver cancers in the transgenic mouse model (Sandgren et al. 1993). 
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Deficits in the expression of TGFA lead to phenotype forms including wavy hairs, 
curly whiskers and altered hair follicle structure (Luetteke et al. 1993; Mann et al. 
1993). TGFA is implicated in wound healing (Schultz et al. 1987), cell migration 
(Barrandon & Green 1987) and bone resorption (Stern et al. 1985). In addition, it has 
been demonstrated that also uncleaved, membrane spanning form of this ligand can 
initiate signal transduction through EGFR on the surface of the contiguous cells in vitro 
(Brachmann et al. 1989; Wong et al. 1989). 
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2.1.3 Betacellulin 
 
2.1.3.1 Structure of betacellulin 
 
Betacellulin is a 32-kilodalton polypeptide growth factor, originally isolated from the 
conditioned medium of a mouse pancreatic tumor β-cell line, βTC3 (Shing et al. 1993). 
BTC is a glycoprotein composed of 80 residues, synthesized as a membrane-spanning 
precursor with 177 amino acids (Figure C). In this form pre-BTC is composed of an 
extracellular part, a transmembrane part and a cytoplasmic part. The extracellular part 
contains a signal peptide for the localization to the secretory pathway and EGF-like 
domain including six cysteine residues forming three characteristic disulfide bonds. In 
EGFR ligands, these intermolecular loops are necessary for recognizing and binding of 
the ligand to the receptor (Carpenter & Cohen 1990). 
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Figure C Structure of a mature human betacellulin. A, B, C disulfide loops within the 
EGF-like domain. 
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A single copy gene for mouse BTC maps to chromosome 5 whereas the human 
betacellulin gene is localized on the chromosome 4 (Pathak et al. 1995). The human and 
bovine precursor BTC share 88% sequence identity, bovine and mouse precursors are 
79% identical, while identity between sequences of human and mouse pre-BTC reaches 
74% (Dunbar & Goddard 2000). The mature form of human betacellulin is released 
after proteolytical cleavage of the precursor protein between Ala31 and Asp32, as well 
as between Y111 and L112 (Shing et al. 1993; Dunbar et al. 1999). This growth factor 
exhibits the strongest affinity to ErbB1 receptor, but it can also bind to receptor dimers 
containing ErbB4. Moreover, the ability of betacellulin to recognize and activate the 
highly oncogenic receptor dimer ErbB2/ErbB3 has been demonstrated (Alimandi et al. 
1997). 
 
2.1.3.2 Expression of betacellulin 
 
Betacellulin is predominantly expressed in pancreas, liver, kidney and small intestine, 
but also in heart, lung, testis, ovary and colon. BTC is also present in various body 
fluids, including milk (Dunbar et al. 1999), suggesting that its absorption trough the 
small intestine influences the neonatal development and that BTC might be an 
important factor for growth and development of various neonatal organs including the 
pancreas. Investigations on fetal and neonatal pancreas demonstrated betacellulin to be 
localized to the primitive duct cells in fetal pancreas and to some islet cell populations 
associated with insulin producing cells (Miyagawa et al. 1999). This growth factor was 
able to stimulate the proliferation of fetal pancreatic epithelial cells and to promote 
growth, differentiation and survival of these cells (Seno et al. 1996; Miyagawa et al. 
1999).  
Betacellulin has been also found in tumor cells, such as mouse sarcoma 180 and 
fibrosarcoma BPV-11 cell lines, also in human breast adenocarcinoma MCF-7 cells 
(Sasada et al. 1993). 
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2.1.3.3 Functions of betacellulin in the endocrine pancreas 
 
Several in vitro and in vivo studies showed a positive impact of BTC on β-cell 
differentiation and insulin production (Watada et al. 1996; Huotari et al. 1998; 
Mashima et al. 1999; Yasuda et al. 2007). Human embryonic stem cells have a very 
wide replication capacity; therefore they could be an efficient and renewable source of 
insulin-producing cells (Demeterco et al. 2000). The treatment of human ES cells with 
betacellulin and nicotinamide has been demonstrated to sustain the expression of PDX1, 
a transcription factor necessary for pancreatic development and β-cell maturation, and 
to induce β-cell differentiation (Cho et al. 2008). Results of several other studies also 
suggest that BTC may modify the activity of several transcriptions factors, known for 
their negative impact on insulin production, and support the activity of the PDX1 gene 
promoter (Watada et al. 1996). One possible explanation of this phenomenon could be 
that BTC causes the demethylation of chromosomal DNA to release the insulin gene 
promoter from inactivation (Watada et al. 1996). 
 
Other in vitro researches showed that the activity of BTC could be intensified in the 
presence of activin A, a member of transforming growth factors-β family of cytokines 
(Mashima et al. 1996; Demeterco et al. 2000). Activin A induces endocrine 
differentiation, whereas BTC shows a mitogenic impact on undifferentiated pancreatic 
epithelial cells (Demeterco et al. 2000). This growth factor has also the ability to 
support betacellulin in converting multipotent pancreatic AR42J cells into pancreatic 
neuroendocrine cells (Mashima et al. 1996). Moreover, studies using a rat fetal pancreas 
cell line indicated the involvement of betacellulin and activin A in the inhibition of 
β-cell division and increase of β-cell volume during pancreas development (Demeterco 
et al. 2000; Yasuda et al. 2007). 
 
Furthermore, application of betacellulin inhibited the expression of amylase and 
glucagon, and elevated the expression of insulin and ghrelin in an in vitro model of 
murine embryonic pancreas (Thowfeequ et al. 2007). However, there is a single study 
not supporting the concept that betacellulin has a significant effect in the improvement 
of glucose metabolism (Sjoholm & Kindmark 1999). 
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Beta-cell regeneration occurs through both increasing the replication of pre-existing 
β-cells and neogenesis from the precursor cells located in the pancreatic duct (Bonner-
Weir et al. 1981; Dutrillaux et al. 1982). There are many studies showing improvement 
of glucose tolerance after treatment with BTC in animal models of diabetes (Yamamoto 
et al. 2000; Li et al. 2001). Hyperglycemia can be caused by administration of β-cell 
toxins such as streptozotozin or alloxan and by pancreatectomy. BTC was shown to 
promote regeneration and neoformation of β-cells mainly from somatostatin- and 
PDX1- positive cells (Li et al. 2008). Yamamoto and colleagues postulated that rhBTC 
(recombinant human BTC) was able to ameliorate glucose tolerance in the alloxan 
treated diabetic mouse by promoting β-cell differentiation from ductal and acinar cells. 
Indeed, injections of rhBTC significantly improved the glucose tolerance and 
contributed to a significant increase in body weight (Yamamoto et al. 2000). 
Additionally, Shin et al. showed a significantly higher level of serum insulin in diabetic 
mice up to two weeks after rAd-BTC (recombinant adenovirus BTC) treatment, 
indicating a positive impact of betacellulin on β-cell regeneration (Shin et al. 2008). 
Also, it is noteworthy that the delivery of a combination of Neurod and BTC genes to 
the liver induced islet neogenesis and reversed diabetes in STZ-treated diabetic mice 
(Kojima et al. 2003). In another diabetic mouse model, mice previously treated with 
STZ, presented a significantly increase of β-cell number and insulin positive islets after 
BTC application (Li et al. 2003). Here, daily administration of betacellulin significantly 
reduced the plasma glucose levels and elevated the plasma insulin concentrations (Li et 
al. 2003). Glucose tolerance tests confirmed the improvement of glucose homeostasis in 
these animals and additional morphometric analysis showed an increased β-cell mass 
without increasing β-cell size. 
 
Potential functions of betacellulin have been demonstrated also in many other organs. 
For instance, BTC was shown to stimulate the proliferation of both normal mammary 
cells and breast tumor cells (Beerli & Hynes 1996; Daly et al. 1999) and to induce the 
terminal phase of mammary epithelial differentiation and secretion (Alimandi et al. 
1997; Pinkas-Kramarski et al. 1998). Transgenic mice ubiquitously overexpressing 
BTC were characterized by high early postnatal mortality, caused by several defects in 
lung, and reduced body weight (Schneider et al. 2005). Additionally, pathological 
alterations like cataract and bone malformations were observed. The study of Dahlhoff 
et al. described several changes in the intestine of the BTC-transgenic mice. The small 
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intestine of transgenic mice was significantly briefer but simultaneously increased in 
weight. Moreover, BTC has been shown to stimulate the cell proliferation in intestinal 
crypts and to support the survival of nascent adenomas in the Apc+/Min mice (Dahlhoff et 
al. 2008). 
 
Similar to many other ligands of the EGFR family, betacellulin is also involved in 
reproduction. Thus, a function for BTC as a mediator of luteinizing hormone, 
prostaglandin and progesterone receptors has been reported (Park et al. 2004; Ashkenazi 
et al. 2005; Shimada et al. 2006). In addition, the studies of Gratao and colleagues on 
the transgenic mice overexpressing betacellulin did not demonstrate any alterations in 
the uterus and ovaries development but exhibited defects in sexual maturity and 
blastocyst implantation (Gratao et al. 2008). 
 
 
2.2 Animal models of diabetes 
 
2.2.1 Pharmacological and surgical induction of diabetes in different animal 
species 
 
There are two types of diabetes mellitus: type 1 and type 2. Diabetes mellitus type 1 is 
an autoimmune disease that results in destruction of insulin producing β-cells in the 
pancreas. Because of lack of insulin, fasting blood glucose in type 1 diabetic patients 
increases enormous (Eisenbarth 2003). Diabetes mellitus type 2 is predicted on 
alterations and dysfunction of insulin receptors leading to insulin resistance or reduced 
insulin sensitivity (Porte, Jr. 1991). 
 
The most common species used as animal models of diabetes are mice, rats, rabbits and 
recently pigs. These animals are often selected because of easy breeding requirements, 
short generation intervals, large number of progeny and the similarity of their 
morphology and pathology to humans (Huge et al. 1995). Other species like nonhuman 
primates, cats or dogs also exhibit many advantages as animal models of human 
diseases, but because of restricted availability and ethical considerations, they are rather 
seldom used. 
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There are many possibilities to induce diabetes in the healthy organism. The most 
commonly used method is application of β-cell toxins such as streptozotocin and 
alloxan (Portha et al. 1974; Waguri et al. 1997; Li et al. 2003; Pomaro et al. 2005). 
These substances can be administrated intraperitoneally, intravenously, subcutaneously 
or orally, depending on the species and aim of investigation. Perfusion of alloxan causes 
destruction of β-cells only in the particular segment of the pancreas, while β-cells in the 
non-perfused segment remain intact. Therefore, this diabetes model allows to clarify, for 
instance, the process of β-cell regeneration from the ductal pancreatic epithelium 
(Yamamoto et al. 2000). Streptozotocin, in contrast, destroys all β-cells in the pancreas 
of the treated animal (Li et al. 2003). 
 
Another method to generate an animal model of diabetes is pancreatectomy, the surgical 
removal of a part or of the whole pancreas (Stump et al. 1988; Li et al. 2001; Kobayashi 
et al. 2004). In this way type 1 diabetes can be induced. However, this technique is 
applied mostly in the large animal models, particularly in the swine. 
 
Because of the similarity of human type 2 diabetes to cat type 2 diabetes mellitus, cats 
have often been used to investigate the insulin resistance (Henson & O'Brien 2006; 
Hoenig 2006). Results of such studies showed that a high supply of glucose had the 
highest impact on β-cell dysfunction. So, it is possible to induce diabetes mellitus using 
only the phenomenon of glucotoxicity on the pancreatic cells (Zini et al. 2009). 
 
2.2.1.1 Mouse 
 
The most common and applied method to induce diabetes in the mouse is infusion of 
alloxan or streptozotocin (Boquist 1977; Boquist & Lorentzon 1980; Leiter et al. 1983; 
Zhao et al. 2005). In addition, the Cre-loxP-mediated gene recombination has been 
applied in order to investigate the role of insulin signaling (Bruning et al. 1998; Michael 
et al. 2000). Dysfunction of major insulin receptors in the target tissues, skeletal muscle, 
resulted in hypertriglyceridemia, however, the glucose metabolism was not impaired 
(Bruning et al. 1998; Michael et al. 2000). Furthermore, obese and leptin-deficient 
(ob/ob) mice are widely employed as mouse models of type 2 diabetes mellitus 
(Coleman 1982; Drel et al. 2006). The lack of leptin, a hormone necessary for the 
appetite regulation, causes uncontrolled food intake and massive obesity in ob/ob mice. 
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Consequently, these mutant mice display several symptoms of type 2 diabetes mellitus 
(Coleman 1982; Drel et al. 2006). 
 
Since 1980, non-obese diabetic mice (NOD) have been employed as a useful animal 
model of type 1 diabetes mellitus. These mice are distinguished by high incidence of 
spontaneous diabetes, resulting from insulitis, what means infiltration and destruction of 
pancreatic cells by the own immune system, particularly by CD4+ and CD8+ T cells 
(Anderson & Bluestone 2005). 
 
A monogenic diabetic mouse model, called Akita mouse, has been established by 
Yoshioka and colleagues (Yoshioka et al. 1997). This diabetic mouse model, 
characterized by early onset, an autosomal dominant mode of inheritance and primary 
dysfunction of β-cells, resembles human maturity onset diabetes of the young (MODY) 
and was employed in different studies to investigante the background of this disease 
(Wang et al. 1999; Izumi et al. 2003). Hyperglycemia in the Akita mice is caused by 
mutation in the insulin 2 gene leading to disruption of an intramolecular disulfide bond 
(Wang et al. 1999). Importantly, Akita mice do not exhibit either obesity or insulitis. 
 
Another diabetic mutant mouse model has been generated using N-ethyl-N-nitrosourea 
(ENU) (Herbach et al. 2007). The Munich Ins2C95Smutant mice exhibited a thymine to 
adenine transversion in the insulin 2 gene at nucleotide position 1903 in exon 3. 
Heterozygous mutant mice demonstrated a significant lower serum insulin level, 
pancreatic insulin content and homeostasis model assasment (HOME), as compared 
with their wild-tipe littermates. 
 
2.2.1.2 Rat 
 
Similar to mice, diabetic rats can be generated by administration of streptozotocin and 
alloxan or through a pancreatectomy. It has been reported that injection of STZ in the 
neonatal rats caused destruction of the most islets and provided an useful model for 
diabetes mellitus (Cantenys et al. 1981; Dutrillaux et al. 1982; Wang et al. 1994). 
Streptozotocin has also been employed as a diabetes-inducing agent in order to 
investigate the structure and functional alteration of the insulin receptor (Kergoat et al. 
1988). In this study, rats with non-insulin-dependent diabetes were employed to 
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demonstrate the lack of significant changes in the insulin receptor autophosphorylation 
between diabetic and healthy animals. 
 
Pancreatectomy is a method of induction of experimental diabetes in the rat as well (Liu 
et al. 2000; Delghingaro-Augusto et al. 2009). Additionally, Goto-Kakizaki rats are also 
useful as animal models of diabetes. Due to defects in the glucose- stimulated insulin 
secretion, Goto-Kakizaki rats spontaneously develop peripheral insulin resistance, 
hyperinsulinemia, and hyperglycemia, observable already 4 weeks after birth. 
Therefore, this model provides a valuable tool for dissecting the pathogenesis of the 
insulin resistance (Chen & Ostenson 2005; Kindel et al. 2009; Matsumoto et al. 2009). 
 
2.2.1.3 Rabbit 
 
Rabbits are also often used as experimental animals for diabetes mellitus. In the most 
studies, diabetes has been induced by administration of the β-cell toxins STZ and 
alloxan (Ragazzi et al. 2002; Choi et al. 2003; Pomaro et al. 2005; Eller et al. 2006; 
Breen et al. 2008; Habibuddin et al. 2008). Nevertheless, surgical techniques in the 
creation of diabetes in rabbits are sometimes employed (Lasserre et al. 2000; Catala et 
al. 2001). 
The experimental rabbits manifested disturbances in the glucose metabolism and 
thereby they could be employed to test new therapy methods of disorders connected 
with diabetes mellitus, like arrhythmias (Zhang et al. 2007), impaired wound healing 
(Breen et al. 2008) or nephropathies (Mumtaz et al. 2004; Mir & Darzi 2009). 
 
2.2.1.4 Pig 
 
While the rodent models are appropriated for answering basic questions of β-cell 
pathophysiology, translational studies, particularly regarding islet transplantations, 
would greatly benefit from large animal models. Pigs seem to be the best candidates for 
this role: they are readily available and produce a large amount of progeny. Also, 
similarities to humans in nutrition, pancreas development and morphology, and 
metabolism make the swine an interesting and useful model for the study of diabetes 
(Huge et al. 1995). 
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Induction of insulin-dependent diabetes in pigs has been achieved by use of 
streptozotocin and alloxan (Marshall 1979; Gabel et al. 1985; Grussner et al. 1993; 
Dixon et al. 1999; Larsen et al. 2002; Larsen et al. 2006; Velander et al. 2008). The 
intravenous administration of 200 mg/kg STZ in Yucatan mini-pigs induced diabetes 
with high mortality as a consequence of massive β-cell destruction (Phillips et al. 1980). 
A mild diabetes mellitus in Göttingen mini-pigs has been reported to originate by 
injection of 80 mg/kg STZ (Kjems et al. 2001). 
 
In humans a 20-30% reduction of β-cell mass leads to an increase of the fasting glucose 
level and abnormalities in the glucose metabolism (Kendall et al. 1990). Similar 
changes are able to be induced in animals using pancreatectomy. Therefore pigs serve as 
an especially appropriate species for such studies. Nevertheless, to induce significant 
hyperglycemia and alterations comparable to humans, it is necessary to remove 80% of 
the porcine pancreas, while a 40% pancreatectomy results only in mild changes (Lohr et 
al. 1989). Several studies described a swine model of diabetes created by a complete 
pancreatectomy (Stump et al. 1988; Kobayashi et al. 2004). The treated animals 
exhibited abnormalities like an increase of the fasting glucose level, decrease of insulin 
secretion, athrophy of hepatocytes and decreased glycogen storage in the liver. These 
findings allow the use of total pancreatectomized pigs to investigate the complications 
of diabetes. 
 
An important aspect supporting the employment of pigs as experimental animals is the 
possibility to obtain insulin-producing tissue from these animals for transplantation 
purposes. Allotransplantations, moving the pancreatic islets from one organism to 
another of the same species, became a useful therapy method against type 1 diabetes 
mellitus. Unfortunately, in humans the discrepancy between the number of recipients 
and the number of donors of pancreatic islets restricts the usage of this therapy in 
clinical practice on a large scale (Shapiro et al. 2000; Shapiro et al. 2006). Therefore, 
pigs might represent a possible source of insulin-producing tissue for transplantations 
into humans (Prabhakaran & Hering 2008). So far, experiments of transplantation of 
pancreatic islets from pigs into rats (Rogers et al. 2006), mice (Wu et al. 2000), dogs 
(Abalovich et al. 2009) or non-human primates(Hering et al. 2006; Dufrane & Gianello 
2008) have been performed. The results of these studies indicate an improved glucose 
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metabolism in the recipient organisms; however, rejection of the xenografts still 
remains the major problem of this therapy. 
 
2.2.1.5 Non-human primates 
 
Reflecting their close phylogenetic relationship with humans (Lu et al. 2008), metabolic 
and hormonal alterations in monkeys seem to be similar to those in humans. Therefore, 
primates would be an excellent animal model of different pathological abnormalities. 
Diabetes mellitus can be initiated in monkeys also by administration of streptozotocin 
or alloxan (Gibbs et al. 1966; Dufrane et al. 2006; Zou et al. 2006), and through a 
partial and total pancreatectomy as well (Qiao et al. 2009). Several studies performed 
on monkeys pointed to an analog glucose metabolism of these animals to humans. Thus, 
50 mg/kg streptozotocin appeared to be the optimal dose to increase the fasting and 
non-fasting blood glucose up to 6-fold and to generate a stable non-human primate 
model with all typical patterns of type 1 diabetes mellitus (Dufrane et al. 2006; Rood et 
al. 2006). 
 
2.2.1.6 Dog and cat 
 
Companion animals such as dogs and cats share the same living environment as humans 
and are exposed to similar illness agents (Kooistra et al. 2009). Feline diabetes mellitus 
closely resembles human type 2 diabetes mellitus (Henson & O'Brien 2006; Kooistra et 
al. 2009), whereas canine diabetes exhibits similarities to human type 1 diabetes 
mellitus (Catchpole et al. 2008). Clinical studies have shown that both living style and 
genetic predispositions are important factors causing diabetes mellitus in cats. 
Moreover, analog to humans, age and obesity were found to be the most important risk 
factors for diabetes in cats (Panciera et al. 1990). 
 
Diabetes in dogs and cats can also be induced by injection of streptozotocin or alloxan 
(Nelson et al. 1990; Anderson et al. 1993) and through pancreatectomy as well (Gupta 
et al. 2002). In the canine diabetes model, the portal insulin levels have been shown to 
determine the suppression of the hepatic glucose production and inhibition of the 
precursors for gluconeogenesis (Fisher et al. 1996; Giacca et al. 1999; Gupta et al. 
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2002). Moreover, a canine model of diabetes has been employed for auto- and xeno-
transplantation experiments (Stagner et al. 2007). 
 
2.2.2 Genetically modified mice in diabetic research 
 
2.2.2.1 Knockout mouse models 
 
Another possibility to investigate the influence of different molecules on β-cells is 
transgenic technology, the mouse being the most frequently employed specie. 
Especially useful are modifications within insulin (Esposito et al. 2003; Yang & Chen 
2009) and leptin receptors (Chen et al. 1996) or a total knockout of genes encoding 
these receptors (Accili et al. 1996; Joshi et al. 1996; Jackerott et al. 2002). Targeted 
disruption of the insulin receptor leads to the development of several metabolic 
disorders including diabetes mellitus (Taylor et al. 1991; Esposito et al. 2003). Mice 
homozygous for a null allele of the insulin receptor gene are born apparently without 
any developmental alterations. However, shortly after birth, the homozygous knockouts 
exhibit a massive hyperglycaemia and hyperketonaemia leading to death due to 
ketoacidosis within 72 hours (Accili et al. 1996). Moreover, a total absence of the 
insulin receptor in the homozygous animals resulted in other metabolic disorders like 
skeletal muscle hypotrophy, increase of the plasma triglyceride level and fatty 
infiltration of the liver (Joshi et al. 1996). Nevertheless, heterozygous mice, lacking 
only one allele of the insulin receptor gene did not develop any metabolic alterations, as 
indicated in the glucose tolerance tests (Joshi et al. 1996). 
 
A proper regulation of the β-cell function depends on cross-talk between leptin and 
insulin signaling pathways (Morioka et al. 2007). Depending on the employed 
transgenic strategy for the creation of a leptin receptor knockout mouse model, the 
influence on glucose metabolism can be different. For instance, knockout mice lacking a 
functional leptin receptor within pancreatic β-cells and hypothalamus developed 
obesity, fasting hypereinsulinemia, impaired glucose-stimulated insulin release and 
glucose intolerance (Covey et al. 2006). Mice lacking the leptin receptor only within 
pancreatic β-cells did not manifest any alterations in insulin sensitivity but exhibited 
improved glucose tolerance due to enhanced insulin secretion which was consistent with 
a lack of tonic inhibitory action of leptin on β cell secretion (Morioka et al. 2007). 
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One of the most important transcription factors for development of the pancreas and 
other foregut structures is pancreatic duodenal homeobox factor-1 (Pdx-1) (Offield et al. 
1996). Knockout mice lacking the Pdx-1 gene exhibit pancreatic agenesis and 
congenital diabetes (Stoffers et al. 1997; Edlund 2001; Johnson et al. 2003). Transgenic 
mice with a haploid deficiency of Pdx-1 demonstrated an impaired glucose metabolism, 
reduced insulin release and β-cell proliferation (Johnson et al. 2003), confirming the 
function of Pdx-1 as a mediator in the glucose-stimulated insulin gene transcription 
(Marshak et al. 1996). 
 
Also the loss of another transcription factor, hepatocyte nuclear factor-1α (HNF-1α), 
leads to body weight reduction and to defective insulin secretory response to glucose 
and arginine in a transgenic mouse model (Fajans et al. 2001). Disruption of this gene in 
mice caused a phenotype similar to one of the six known genetic forms of maturity 
onset diabetes in the young (MODY), namely MODY-3. Due to such investigations, the 
involvement of HNF-1α in the regulation of β-cell differentiation and β-cell mass has 
been uncovered. 
 
Signal transducer and activator of transcription 3 (STAT3) deficient mice have been 
generated in order to investigate the function of this ubiquitous transcription factor on 
the postnatal glucose homeostasis (Cui et al. 2004). This study revealed the 
development of diabetes mellitus, including body weight reduction, hyperglycaemia and 
hyperinsulinemia, in mice lacking STAT3 within hypothalamus and pancreatic β-cells 
(Cui et al. 2004). 
 
Studies investigating mouse models with a dysfunction of either cyclin D or partner 
cyclin-dependent protein kinase (Cdk) demonstrated an important role of these 
molecules for a proper β-cells proliferation and insulin synthesis (Rane & Reddy 2000; 
Georgia & Bhushan 2004). Cyclin D2-/- mice exhibited insulin-deficient diabetes caused 
by reduced postnatal α- and β-cell replication. Cdk-4-/- mice showed abnormalities 
similar to cyclin D2-deficient mice; in addition, the body weight of the knockout 
animals was 40% lower than wild-type controls (Martin et al. 2003). 
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Glucokinase (GLK) is a member of the hexokinase family and responsible for the 
phosphorylation of glucose to glucose-6-phosphate. This serves as a glucose-sensing 
mechanism for regulation of the insulin secretion in the pancreatic β-cells (Meglasson & 
Matschinsky 1986). Knockout mouse models confirmed a crucial role of glucokinase in 
the glucose metabolism. GLK-deficient mice generated by Grupe and colleagues 
showed massive hyperglycaemia and hyperacidemia, and died during the first five days 
after birth (Grupe et al. 1995). Nevertheless, mice with one functioning GLK allele 
developed only mild diabetes, comparable to MODY in humans (Grupe et al. 1995). 
 
2.2.2.2 Transgenic mouse models 
 
Transgenesis became a widespread strategy to create appropriate animal models for 
investigations on diabetes mellitus and for developing possible therapy methods. An 
important aspect in the generation of transgenic mouse lines is selection of an adequate 
promoter to control the expression of the transgene. 
The most commonly used promoter in diabetes research is the insulin promoter. In 
different studies rat, mouse, porcine or human insulin promoters have been applied to 
induce diabetes in the transgenic mouse models (Inada et al. 2004; Anneren et al. 2007; 
Hara et al. 2007; Watanabe et al. 2007). 
 
The employment of transgenic mice overexpressing hormones (Davani et al. 2004), 
tyrosine kinases (Anneren et al. 2007), transcription factors (Jackerott et al. 2006) or 
enzymes (Kebede et al. 2008) supported investigations concerning the function of these 
molecules in the development of diabetes. For instance, expression of a dominant 
negative glucose-dependent insulinotropic polypeptide receptor (GIPRdn) under the 
control of the rat proinsulin gene promoter induced diabetes mellitus in transgenic mice 
(Herbach et al. 2005). Also Kebede and colleagues showed that overexpression of 
fructose-1,6-bisphosphatase, a gluconeogenic enzyme upregulated in the pancreatic 
islets, under the rat insulin promoter contributed to insulin secretory dysfunction, 
increase of the serum glucose level and finally to the development of type 2 diabetes 
mellitus (Kebede et al. 2008). 
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A proper function of signal transducers and activators of transcription (STAT) proteins 
has been shown to be crucial for an adequate prenatal development (Cui et al. 2004; 
Yashpal et al. 2004). The rat insulin promoter has been employed to control the 
transcription of a dominant-negative and a constitutive active mutant form of the 
STAT5 gene (Jackerott et al. 2006). Due to these investigations, a role for STAT5 in 
glucose homeostasis has been uncovered. 
 
Furthermore, the employment of a rat insulin promoter confirmed the diabetogenic role 
of glucocorticoids (Davani et al. 2004). Mice overexpressing the rat glucocorticoid 
receptor under the control of the rat insulin promoter showed an inhibited insulin 
secretion, hyperglycaemia and impaired glucose tolerance (Davani et al. 2004). 
 
However, the rat insulin promoter is not the only one used in the diabetes research. 
Hara et al. employed a mouse insulin promoter causing the overexpression of the 
hepatocyte nuclear factor-6 and detected a significant loss of β-cell mass in transgenic 
mice (Hara et al. 2007). A diabetic mouse model has also been generated using a mutant 
form of the hepatocyte nuclear factor-1α regulated by the porcine insulin promoter 
(Watanabe et al. 2007). Results of this study indicated that expression of the transgene 
driven by the porcine insulin promoter induced a decrease in body weight, disturbed 
islet neogenesis and impaired insulin secretion in transgenic mice (Watanabe et al. 
2007). 
 
Insulin promoters have also often been applied to regulate the expression of molecules 
known to ameliorate the diabetic phenotype in mice. Miyawaki and colleagues 
demonstrated that overexpression of a cyclin-dependent kinase 4 in β-cells under the 
control of the human insulin promoter (HIP) led to glycaemic normalization and to 
improved plasma lipid concentration in transgenic, obese and insulin resistant db/db 
mice (Miyawaki et al. 2008). Moreover, a human insulin promoter has been useful for 
investigations on potentially protective impact of a programmed death-1 ligand (PD-L1) 
against autoimmune diabetes (Wang et al. 2008). In this study a human insulin promoter 
regulated the overexpression of PD-L1 in the pancreatic β-cells in the non-obese 
diabetic (NOD) mice. The proliferation rate of diabetogenic T-cells in the transgenic 
NOD mice was significantly reduced. Furthermore, a diabetic phenotype appeared in 
the transgenic animals significantly slower than in the control NOD mice. 
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A significant improvement of the glucose metabolism has been observed in transgenic 
mice expressing the hepatocyte growth factor in β-cells under the control of the rat 
insulin promoter (Garcia-Ocana et al. 2001). These animals exhibited an increased islet 
size and islet number, as well as insulin-mediated hypoglycaemia, suggesting a positive 
impact of this growth factor on the endocrine pancreas (Garcia-Ocana et al. 2001). 
 
Although the insulin promoter is the most frequently used in the research on glucose 
metabolism, there are also some studies employing a promoter sequence of the mouse 
metallothinein-I gene (Portanova et al. 1990; Robertson et al. 2008). Overexpression of 
both the insulin-like growth factor I (IGF-I) (Robertson et al. 2008) and the human 
growth factor (hGH) (Portanova et al. 1990) in transgenic animals resulted in body 
weight reduction, significant hypoglycaemia and elevated glucose metabolism. 
However, the widespread expression of the transgene in these mouse models can be a 
complicating factor for the interpretation of the results. 
 
A new mouse model, introduced in the following study, provides a possibility to achive 
β-cell-specific expression of different gene products and to investigate potential effects 
of these products in new therapies against diabetes mellitus. 
Specific transgene expression in β-cells 
28 
Accepted for publication by the Molecular and Cellular Endocrinology,  
5th of August 2009 
 
 
 
 
Specific transgene expression in mouse pancreatic β-cells 
under the control of the porcine insulin promoter 
 
Marjeta Grzech1, Maik Dahlhoff1, Nadja Herbach2, Felix A. Habermann3, Ingrid Renner-
Müller1, Rüdiger Wanke2, Heinrich Flaswinkel1, Eckhard Wolf1,4, Marlon R. Schneider1 
 
 
1Chair for Molecular Animal Breeding and Biotechnology, 4and Laboratory for Functional Genome 
Analysis (LAFUGA), Gene Center, LMU Munich, Munich, Germany; 
2Institute of Veterinary Pathology, Center for Clinical Veterinary Medicine, LMU Munich, Munich, 
Germany; 
3Chair for Veterinary Anatomy, Histology and Embryology, Department of Veterinary Sciences, LMU 
Munich, Munich, Germany 
 
 
 
Address all correspondence to: 
Dr. Marlon R. Schneider, Chair for Molecular Animal Breeding and Biotechnology, Gene Center, LMU 
Munich, Feodor-Lynen-Str. 25, 81377 Munich, Germany, Telephone: +49 89 218076815, Fax: +49 89 
218076849, e-mail: schnder@lmb.uni-muenchen.de 
 
 
Running head: 
Transgene expression under the porcine insulin promoter 
 
 
 
 
 
Specific transgene expression in β-cells 
29 
Abstract 
 
 
The availability of regulatory sequences directing tissue-specific expression of 
transgenes in genetically modified mice and large animals is a prerequisite for the 
development of adequate models for human diseases. The rat insulin 2 gene (Ins2) 
promoter, widely used to achieve transgene expression in pancreatic β-cells of mice, 
also directs expression to extrapancreatic tissues and performs poorly in isolated 
pancreatic islets of human, mouse, and pig. To evaluate whether the full 5’ untranslated 
region (UTR) of the porcine insulin gene (INS) confers robust and specific expression 
in β-cells we generated an expression cassette containing 1500 bp of the porcine INS 5’ 
UTR and the 3’ UTR of the bovine growth hormone gene (GH). The cassette was 
designed to allow easy exchange of the sequences to be expressed and easy removal of 
the vector backbone from the expression cassette. To evaluate the properties of the 
cassette, we initially inserted a cDNA encoding human betacellulin, a growth factor 
known to affect structural and functional parameters of β-cells. After confirming the 
functionality and specificity of the construct in vitro, transgenic mouse lines were 
generated by pronuclear DNA microinjection. Using RT-PCR, immunohistochemistry 
and immunofluorescence, we show that transgenic mice expressed human betacellulin 
exclusively in β-cells. Confirming the proposed insulinotropic effect of betacellulin, 
transgenic mice showed improved glucose tolerance. We conclude that the newly 
designed expression cassette containing 1.500 bp of the porcine insulin promoter 5’ 
UTR confers robust and specific transgene expression to β-cells in vitro and in 
transgenic mice. 
 
Keywords: porcine insulin promoter, transgenic mice, betacellulin, EGFR, glucose 
tolerance test. 
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1 Introduction 
 
 
Genetically modified mice greatly contributed to advance our understanding of the 
physiology and pathology of the endocrine pancreas. A key component of this 
technology is the targeted expression of gene products in specific cell types of the 
pancreatic islets. The rat (Hanahan 1985; Dahl et al. 1996; Vasavada et al. 1996), 
mouse (Hara et al. 2003), and human (Hotta et al. 1998; Krakowski et al. 1999) insulin 
promoters have been frequently used to direct expression of oncogenes, hormones, 
growth factors, transcription factors, reporter genes, and more recently of the enzyme 
Cre recombinase (Ahlgren et al. 1998; Postic et al. 1999; Gannon et al. 2000; Dor et al. 
2004) specifically to pancreatic β-cells in transgenic mice. A major caveat of the rat 
insulin promoter, however, is the reported ectopic expression in certain areas of the 
brain, potentially resulting in phenotypes in both β-cells and neural cells (Gannon et al. 
2000; Martin et al. 2003). 
 
While the mouse model is appropriate for answering basic questions of β-cell 
pathophysiology, translational studies, particularly regarding islet transplantation, 
would greatly benefit from large animal models. Pigs seem to be the best candidates for 
this purpose: they are readily available, produce a large progeny, and regulate blood 
glucose levels similarly to humans. In addition, porcine neonatal islet cell clusters  
(MacKenzie et al. 2003; Cardona et al. 2006) and islets from adult pigs (Hering et al. 
2006) are an interesting source of insulin-producing tissue for transplantation purposes. 
In this regard, there is an urgent need of genetic tools for the tissue-specific delivery of 
gene products to porcine pancreatic β-cells. Unfortunately, the rat insulin promoter was 
shown to perform very poorly in isolated islets from pigs, humans, and mice (Londrigan 
et al. 2007). The porcine insulin gene (INS) contains three exons and two introns, and 
highly conserved cis-acting elements were identified in the 5’ flanking region (Han & 
Tuch 2001). Recently, a fragment of the porcine INS promoter containing 
approximately 680 bp of the 5’ untranslated region (UTR) was active in a cell type-
specific manner in vitro, but failed to confer expression in transgenic mice (Watanabe et 
al. 2007). Addition of a cytomegalovirus enhancer resulted in transgene expression both 
in vivo and in vitro, but at the expense of cell type specificity (Watanabe et al. 2007). 
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Here, we report that an expression cassette containing 1500 bp of the 5’ UTR from the 
porcine INS gene (including the first exon and the first intron) and the 3’ UTR of the 
bovine growth hormone gene (GH) is efficient to drive transgene expression in a robust 
and specific manner to β-cells in vitro and in transgenic mouse models. To test the 
functionality of the cassette we have chosen the cDNA encoding human betacellulin, a 
ligand of the EGFR (Schneider & Wolf 2009) known to stimulate β-cell differentiation 
in vitro and to improve glucose tolerance in diabetic models and in transgenic mice. 
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2 Material and Methods 
 
 
2.1 Construction of the transgene 
A ~1500-bp fragment of the 5’ flanking region of the porcine insulin gene (INS) was 
amplified by polymerase chain reaction (Expand High FidelityPLUS PCR System, Roche 
Diagnostics, Mannheim, Germany) using the sense primer (SalI restriction site 
underlined) 5’-TGT ACT GTC GAC GAG TTC AGC TGA GCT GGC TC-3’ and the 
antisense primer (HindIII restriction site underlined) 5’-CGC TAG AAG CTT TGG 
GGG ACG GGC GGC GTT-3’ (see Figure 1A). Template was a plasmid pGEM+INS 
(Flaswinkel et al., unpublished) containing the whole porcine INS gene. The human (h) 
betacellulin (BTC) cDNA was amplified with the same PCR system employing the pTB 
1560 vector (a gift of Dr. Y. Shing, Children’s Hospital, Boston, MA) as a template and 
the primers (HindIII restriction site underlined) 5’-ACT AAG CTT CAC CCC CCG 
CCA TGG ACC GGG CCG CCC GGT-3’, sense, and (EcoRV restriction site 
underlined, HA-tag in bold) 5’-TAG GAT ATC TTA AGC GTA GTC TGG GAC 
GTC GTA TGG GTA AGC AAT ATT TGT CTC TTC AAT ATC-3’, antisense. 
The PCR products were cloned into the pCRII-TOPO vector (Invitrogen, Carlsbad, CA) 
and Sp6/T7-sequenced to confirm amplification fidelity. The porcine INS promoter 
(PIP) was then subcloned into the SalI and HindIII sites of a pBluescript vector 
(Stratagene, La Jolla, CA) containing the bovine (b) GH 3’ untranslated region and 
polyadenylation signal (pA) within its XbaI and NotI sites (Figure 1B). Next, the BTC 
cDNA was cloned as a HindIII/EcoRV fragment between PIP and bGHpA (Figure 1B). 
Correct positioning of each element was confirmed by restriction enzyme digests and 
sequencing from the PIP through the hBTC cDNA into the bGHpA using the primer 5’-
CATCTCGGCAGGAGGACGT-3’ (Figure 1A). 
 
2.2 Cell transfection 
All cell culture reagents were purchased from PAA (Pasching, Austria). Immortalized 
mouse hepatocytes (a gift from Dr. D. Accili, Columbia University, NY), human 
embryonal kidney 293 cells (HEK 293), and the MIN-6 mouse pancreatic β-cell line (a 
gift from Dr. J. Miyazaki, Osaka University) were cultured in low glucose (1 g/L) 
DMEM medium with 10% fetal bovine serum. 2x106 cells were transfected either with 
the PIP-hBTC construct or with the pGMAX-GFP vector using the Amaxa Nucleofector 
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system (Lonza, Cologne, Germany). After transfection cells were cultured in high 
glucose medium (4.5 g/L) for 48 hours and harvested for protein isolation. 
 
2.3 Western blot analyses 
Cells were homogenized in lysis buffer (Cell Signaling, Danvers, MA, USA) and 30 µg 
total protein were separated by SDS-PAGE and transferred to PVDF membranes by 
electroblotting. Loading of equal amounts of protein for each sample was verified with 
Ponceau staining. A rabbit antibody that reacts specifically with human BTC (R&D, 
Systems, Wiesbaden, Germany) and a secondary HRP-conjugated goat anti-rabbit-
antibody (Cell Signaling) were employed. Bound antibodies were detected using an 
enhanced chemiluminescence detection reagent (ECL Advance Western Blotting 
detection kit, GE Healthcare) and appropriate x-ray films (GE Healthcare). 
 
2.4 Generation of transgenic mice 
The PIP-hBTC expression cassette was released from the vector backbone by SalI/NotI 
double digestion, purified by agarose gel electrophoresis, diluted to 2 ng/µl in injection 
buffer (Nagy et al. 2003) and employed for pronuclear microinjection into fertilized 
oocytes from the inbred strain FVB/N. The injected zygotes were transplanted into the 
oviducts of pseudopregnant females and potential founder animals were screened by 
PCR. The animals had free access to a standard rodent diet (V1534, Ssniff, Soest, 
Germany) and water. All experiments were approved by the author’s institutional 
committee on animal care and carried out in accordance with the German Animal 
Protection Law with permission from the responsible veterinary authority. 
 
2.5 Immunohistochemistry and immunofluorescence 
Animals were anesthetized and killed by cervical dislocation. Pancreata and other 
organs were removed immediately after the animal’s death, carefully trimmed free of 
adjacent tissues, weighed, fixed in 4% paraformaldehyde (in PBS, pH 7.4) and 
embedded in paraffin. For immunohistochemical localization of BTC, the streptavidin-
biotin method was applied. Five µm thick sections were cut, deparaffinized and heated 
for 20 min in a microwave in 10 mM sodium citrate buffer for antigen retrieval. The 
primary antibody (same as for Western blot, dilution 1:300) was incubated for 2 hours 
at room temperature, followed by a biotin-conjugated rabbit anti-goat secondary 
antibody (Dako, Hamburg, Germany). Diaminobenzidine (Sigma, Taufkirchen, 
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Germany) served as chromogen. Finally, the sections were counterstained with 
hematoxylin. Colocalization of BTC with insulin and glucagon was studied by 
multicolor immunofluorescence: Five µm paraffin sections pretreated as described 
above were incubated for 1 hour at room temperature with the primary antibodies 
diluted in Tris-buffered saline (TBS, pH 7.6). After three washes with TBS, sections 
were incubated for 1 hour with fluorescence-labeled secondary antibodies. We used the 
previously described goat anti-human BTC antibody (R&D, Systems, Wiesbaden, 
Germany), rabbit anti-glucagon and guinea pig anti-insulin antibodies (Dako, Hamburg, 
Germany). The secondary antibodies all rose in donkey and coupled to FITC, Cy3, or 
Cy5 were from Dianova (Hamburg, Germany). After the last washing step, slides were 
mounted with Vectashield antifade solution (Vector Laboratories, Grünberg, Germany) 
containing DAPI as a nuclear counterstain. Confocal optical sections (pixel size 50 x 50 
nm, pinhole size 1 Airy unit corresponding to an optical thickness of 0.7 - 1 µm) were 
recorded using a confocal laser scanning microscope (LSM 510 Meta, Zeiss, 
Oberkochen, Germany) with a 40 × PlanNeofluar oil immersion objective (NA 1.3). For 
excitation of DAPI, FITC, TRITC and Cy5 laser lines of 364, 488, 543 and 633 nm 
were used. Fluorescence signals were detected through the following emission filters: 
BP 385 - 470 nm for DAPI, BP 505 - 530 nm for FITC, BP 560 - 615 for Cy3 and LP 
650 for Cy5. A polychromatic multichannel detector (Meta detector, Zeiss) was used to 
discriminate autofluorescence from immunofluorescence signals. 
 
2.6 Reverse transcriptase PCR 
Isolation of total RNA, first strand cDNA synthesis, and semiquantitative RT-PCR were 
performed as described earlier (Schneider et al. 2001). The primers previously 
described for amplifying the human BTC cDNA were employed for the detection of 
transgene-specific BTC mRNA expression. The integrity of the template cDNA was 
confirmed by amplifying a sequence of the β-actin gene (sense, 
5’-GGCATCGTGATGGACTCC-3’; antisense, 5’-GTCGGAAGGTGGACAGGG-3’). 
 
2.7 Glucose metabolism studies 
After fasting for 14 hours, blood was drawn from the retro-orbital sinus of ether 
anesthetized mice for determination of blood glucose. For glucose tolerance test, fasted 
mice (16 hours) were injected intraperitoneally with glucose (1.5 g/kg body weight). 
Blood samples were obtained by puncture of the tail vein immediately before glucose 
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administration and at the indicated time points after injection. A glucometer (Precision, 
Abbott Diabetes Care, Wiesbaden, Germany) was used to determine glucose levels. 
 
2.8 Statistical analyses  
The results of glucose tolerance tests were statistically evaluated by analysis of variance 
(Linear Mixed Models; SAS 8.2; PROC MIXED), taking the fixed effects of Group 
(transgenic vs. control), Time (relative to glucose application) and the interaction 
Group*Time as well as the random effect of Animal into account (Verbeke & 
Molenberghs 2001). 
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3 Results 
 
 
3.1 Evaluation of promoter activity in vitro 
To evaluate the overall functionality and specificity of the construct, cell lines 
representing different cell types were transfected either with the PIP-hBTC or with the 
pMAX-GFP vector. Transfection efficiency, evaluated 24 hours after the transfection by 
monitoring GFP fluorescence, was similar for all lines (~50% green cells, data not 
shown). After 48 hours, cells transfected with PIP-hBTC were harvested for protein 
isolation and subjected to Western blot analysis employing an antibody that recognizes 
specifically human BTC. As shown in Figure 1C, human BTC was clearly detected in 
protein extracts from mouse MIN-6 β-cells, but not in extracts from mouse hepatocytes 
or human embryonic kidney (HEK 293) cells. These in vitro findings indicate that the 
PIP-hBTC construct is functional and suggest that the employed porcine insulin 
promoter is selectively activated in β-cells. 
 
3.2 Generation of PIP-hBTC transgenic mice 
After microinjection of the PIP-hBTC construct, forty mice were born and three of them 
were identified as being transgenic by PCR and Southern blot analyses (data not 
shown). One transgenic animal (#11) consistently failed to generate transgenic progeny 
and was therefore sacrificed. The remaining two founders (#16 and #38) transmitted the 
transgene to their descendents in a mendelian fashion, originating two PIP-hBTC 
transgenic lines (L2 and L3, respectively). 
 
3.3 Specific expression of the PIP-hBTC transgene in insulin-positive cells of the 
endocrine pancreas 
To evaluate expression of the construct in different organs, RT-PCR analysis was 
performed for RNA samples from lung, liver, small intestine, kidney, muscle, and 
pancreatic islets. As shown in Figure 2A, transgene expression was detected 
exclusively in the pancreatic islets in L2 transgenic mice. The same result was obtained 
for L3 mice (data not shown). Immunohistochemistry against hBTC also failed to detect 
positive cells in the above mentioned and additional organs such as the heart, stomach 
and brain (data not shown). To evaluate whether the used porcine insulin promoter 
directs expression to certain regions of the ventral brain, as described for the rat insulin 
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promoter (Gannon et al. 2000a), we additionally studied the pons, caudate putamen, and 
the hypothalamus. In none of these brain regions we detected transgene transcripts by 
RT-PCR (Figure 2B) or hBTC by immunohistochemistry (data not shown). In the 
pancreas of L2 and L3 transgenic mice, hBTC-positive cells were readily detected 
within the islets, but not in the exocrine compartment (Figure 2C). The number of cells 
expressing the transgene was considerably higher in the islets of L3 transgenic mice as 
compared to founder #11 and L2 animals (Figure 2D). To further evaluate whether the 
employed PIP sequence specifically directs expression of the transgene to insulin-
producing cells, we examined colocalization of hBTC with insulin and glucagon by 
multicolor immunofluorescence and confocal laser scanning microscopy. In both 
transgenic PIP-hBTC and non-transgenic control mice, insulin-specific 
immunofluorescence was evident in the cytoplasm of the majority of islets cells, while a 
smaller proportion of the cells were negative for insulin and positive for glucagon 
(Figure 2E). Importantly, in transgenic animals, hBTC staining was only observed in 
insulin-positive cells, indicating that the PIP sequence employed is adequate for 
targeting exclusively pancreatic β-cells (Figure 2E). Evaluation of pancreatic islets 
from transgenic fetuses sacrificed on day 17.5 of pregnancy revealed that the β-cell 
specificity of the employed promoter is already present at this early stage of islet 
formation (Figure 2F). 
 
3.4 PIP-hBTC transgenic mice show no overt phenotypic abnormalities  
Transgenic mice from both lines developed normally, were fertile, and did not show any 
obvious abnormalities. Histological analysis of the pancreas did not reveal any 
pathological alteration in PIP-hBTC transgenic mice, in agreement with our previous 
results in mice with overexpression of BTC in both the exocrine and the endocrine 
compartment (Dahlhoff et al. 2009c). Body and organ weights were evaluated in 
transgenic males and females and gender-matched littermates at the age of 5 months 
(n=4-6/group). No differences were observed in total body weight, and in absolute or 
relative organ weights, irrespective of the line (data not shown). 
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3.5 PIP-hBTC transgenic mice show improved glucose tolerance 
Intraperitoneal glucose tolerance tests showed that the blood glucose concentrations 
rose similarly in control and in PIP-hBTC transgenic mice from line 2 and 3 after 
glucose injection (Figure 3A). However, glucose clearance was improved in transgenic 
mice from both lines in the second half of the test period (Figure 3A). When the results 
were expressed as area under the glucose curve, a significant difference was observed 
between L2 and L3 transgenic mice and their control littermates, respectively 
(Figure 3B). 
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4 Discussion 
 
 
Here we show that an expression cassette containing 1500 bp of the 5’ UTR from the 
porcine insulin gene (including the first exon and the first intron) and the 3’ UTR of the 
bovine GH gene is efficient for driving transgene expression in a robust and specific 
manner to β-cells in vitro and in transgenic mice. 
 
To test the functionality of the cassette we have chosen a cDNA encoding the EGFR 
ligand betacellulin (Schneider & Wolf 2009). Betacellulin is known to stimulate β-cell 
differentiation in vitro and to improve glucose tolerance in diabetic models and in 
transgenic mice (reviewed in Dahlhoff et al. 2009) - although a few studies failed to 
demonstrate such an effect (Sjoholm & Kindmark 1999). Recently, we demonstrated an 
improved glucose tolerance in mice with ubiquitous overexpression of betacellulin 
(Schneider et al. 2005; Dahlhoff et al. 2009). This finding needed cautious 
interpretation, since betacellulin levels were also increased in other tissues. In the 
present study we demonstrate an improved glucose tolerance in an animal model with 
β-cell-specific overexpression of betacellulin. Also in agreement with our previous 
results is the lack of pathological alterations in PIP-hBTC transgenic mice. This is in 
contrast to the multiple pathological effects including islet disaggregation, fibrosis, and 
even ductal metaplasia observed in transgenic mice with β-cell-specific overexpression 
of the EGFR ligands EGF (Krakowski et al. 1999) and heparin-binding EGF (Means et 
al. 2003). This observation indicates that BTC has unique actions on pancreatic islets as 
compared to other EGFR ligands. The transgenic mouse lines described here are 
valuable for detailed studies of glucose metabolism and β-cell regeneration following 
induction of diabetes e.g. after injection of streptozotocin. 
 
The new expression cassette described here represents a significant improvement over 
available expression systems in different ways. First, our cassette potentially allows β-
cell-specific expression of gene products in transgenic mice without the unwanted 
expression in other tissues such as the central nervous system. Nevertheless, the level 
and specificity of transgene expression in new lines are always difficult to predict due to 
position effects and require careful characterization (Martin & Whitelaw 1996). Second, 
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the ease of exchanging the sequences to be expressed in the cassette and the availability 
of restriction sites for “rare cutter” enzymes for removing the relevant sequences from 
the vector backbone render this construct a handy tool for the generation of transgenic 
mice for β-cell specific overexpression of a variety of proteins. Third, it is plausible to 
predict that the transgene cassette will also perform well in pigs, promoting a 
widespread use of this species in diabetes research. 
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Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Generation of the PIP-hBTC construct. A: nucleotide sequence of the porcine insulin 
gene sequence employed in this study. The 5’ flanking region is shown in lower case (the 
consensus TATA box is shown in bold). The transcription initiation site is underlined, the 
transcribed sequence is shown in upper case (cDNA sequence in bold). The translation initiation 
site is double-underlined and the sequence of the primers used to amplify the promoter is boxed. 
The sequence changed to a HindIII site (AAGCTT) in the second primer is highlighted in grey. 
B: schematic representation of the construct employed to generate transgenic mice including the 
position of relevant restriction sites. C: Western blot analysis of hepatocytes (1), kidney cells 
(2) and MIN-6 β-cells (3) transfected with the PIP-hBTC construct showing expression of 
human BTC exclusively in the β-cells. Staining of an unspecific band is shown as a loading 
control.
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Figure 2 Tissue and cell-specific expression of the PIP-hBTC construct in transgenic mice. 
A, B: RT-PCR analysis showing that transgene transcription is restricted to the pancreatic islets. 
Data in A are from L2 animals. C.P.: caudate putamen. C: Immunohistochemical staining of 
hBTC showing exclusive transgene protein expression within the pancreatic islets of L3 
transgenic mice. D: Immunohistochemical detection of hBTC in the islets of transgenic mice as 
compared to non-transgenic control mice at higher magnification. Scale bars represent 500 µm 
in C and 50 µm in D. E, F: Simultaneous visualization of insulin, glucagon, and hBTC by 
multicolor immunofluorescence and confocal laser scanning microscopy in the islets of an adult 
PIP-hBTC (E), an adult non-transgenic control mouse (insert in E), and a PIP-hBTC fetus at day 
17.5 of pregnancy (F). 
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Figure 3 Glucose metabolism in BTC-tg mice. Intraperitoneal glucose tolerance test (A) 
revealed a significant reduction of the area under the curve (AUC, B) in PIP-hBTC transgenic 
mice from L2 and L3 as compared to control littermates. Values represent means ± SEM of two 
independent experiments for L2 and L3. *: P < 0.05. 
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4 DISCUSSION 
 
 
In the present study transgenic mice overexpressing human betacellulin under the 
control of the porcine insulin promoter were generated in order to investigate the ability 
of a new cassette to direct expression of the transgene specifically to the pancreatic 
β-cells. Both in vitro and in vivo analyses performed in this study showed that the 
expression cassette containing 1500 base pairs of the 5’ UTR (untranslated region) from 
the porcine insulin gene and the 3’ UTR of the bovine GH gene efficiently drives the 
transgene expression in a robust and specific manner to β-cells. Other advantages of this 
new construct are the ease of exchanging the sequences to be expressed in the cassette 
and the availability of restriction sites for “rare cutter” enzymes for removing the 
relevant sequences from the vector backbone. It renders this construct a handy tool for 
the generation of transgenic mice with β-cell specific overexpression of a variety of 
proteins. 
 
The employment of insulin promoters in transgenic technology became a useful strategy 
to create animal models exhibiting not only diabetic symptoms but also an improved 
glucose metabolism. Transgenic animals overexpressing, for example, hepatocyte 
growth factor (Garcia-Ocana et al. 2001), pituitary adenylate cyclase-activating 
polypeptide (PACAP) (Yamamoto et al. 2003) or hepatocyte nuclear factor-1 α 
(Watanabe et al. 2007) under the control of the rat, human or porcine insulin promoter 
permitted to investigate the potentially positive function of these proteins in the insulin 
secretion and blood glucose reduction. Moreover, the usage of experimental diabetic 
mice with an transgenic overexpression of hyperglycaemia-avoiding molecules driven 
by insulin promoters (Miyawaki et al. 2008; Wang et al. 2008) demonstrated a possibly 
therapeutic approach to prevent the progression of diabetes mellitus in patients. 
 
Depending on the employed promoter, the targeted gene can be expressed in many 
different organs (Sandgren et al. 1990) or in one or more particular tissues (Yamamoto 
et al. 2003; Burkhardt et al. 2006). Also position effects can be an obstacle in the 
creation of a transgenic animal lines with a tissue specific expression of the transgene 
(Festenstein et al. 1996). The frequently used rat insulin promoter has been shown to 
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induce the transcription of the transgene not only in the pancreas but also in some parts 
of the brain, including hypothalamus (Gannon et al. 2000; Covey et al. 2006). In the 
present study the porcine insulin promoter was employed to elicit a β-cell specific 
expression of the transgene with the long-term goal of generating BTC transgenic pigs. 
 
Importantly, both PIP-hBTC transgenic mouse lines 2 and 3 used in the presenting study 
expressed the hBTC-mRNA solely within the islets of Langerhans. Reverse 
transcription PCR and immunhistochemical staining of different organs from the wild-
type and transgenic mice against hBTC supported the conclusion of islet-specificity of 
the expression. Investigations using a multicolour immunofluorescence confirmed the 
β-cell specificity of the expression. Moreover, additional analyses of several brain areas 
of the transgenic animals confirmed the islet-specificity. 
 
The potential of the PIP promoter to direct the β-cell specific expression of the 
transgene may stimulate the creation of large transgenic animal models overexpressing 
anti-diabetic agents solely in the pancreatic islets. Such an approach could be 
particularly worthwhile in the generation of transgenic pigs as donors for 
transplantations of the pancreatic islets into humans. Furthermore, results of the 
previous investigations (Yamamoto et al. 2000; Dahlhoff et al. 2009) and of the present 
study as well confirm betacellulin as an effective factor improving the glucose 
homeostasis and preventing diabetes mellitus. 
 
Molecular analysis of the porcine insulin gene and promoter (German et al. 1995; 
Ohneda et al. 2000; Melloul et al. 2002) provide a background for understanding the 
strict β-cell-associated insulin transcription. It has been demonstrated that regulation of 
the insulin gene occurs by various cis-acting elements localized in the 5’-flanking 
region of the insulin promoter (German et al. 1995; Ohneda et al. 2000). These 
elements are potentially able to induce the β-cell specific transcription of any gene 
placed downstream. This activity of the porcine insulin promoter has been also 
employed to regulate the expression of genes of interest in vitro and in vivo (Watanabe 
et al. 2007). However, so far there are hardly publications describing animal models 
with a porcine insulin promoter to direct the expression of a transgene. 
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During mouse embryogenesis, the insulin-containing cells appear in the dorsal 
pancreatic bud at embryonic day (E) 11.5 and one or two days later in the ventral 
pancreatic bud (Herrera et al. 1991). At E 18.5 the typical islets are already formed with 
the centrally located β-cells surrounded by other endocrine cells (Herrera et al. 1991). 
The immunohistochemical analyses of pancreatic tissue of the PIP-hBTC transgenic and 
wild type mice from E 17.5 detected expression of the transgene in the originating 
pancreatic islets, demonstrating activity of the porcine insulin promoter already during 
the embryonic development. Nevertheless, expression of the transgene under control of 
the mouse PDX1 promoter in the embryonic pancreas was detectable already at E 12.0 
(Dichmann et al. 2003). 
 
A positive effect of betacellulin on the stimulation of β-cell differentiation (Mashima et 
al. 1996; Thowfeequ et al. 2007) and increase of insulin production (Mashima et al. 
1996; Huotari et al. 1998;) was previously showed via in vitro investigations. 
Importantly, PIP-hBTC transgenic mice from lines 2 and 3 generated in the present 
study exhibited an improved glucose tolerance. These results confirm the results of 
other studies involving the overexpression of this growth factor in a mouse model 
(Schneider et al. 2005; Dahlhoff et al. 2009), suggesting a positive effect of this protein 
also in the glucose homeostasis. However, it must be considered that in the above 
mentioned studies betacellulin levels were elevated not only within the pancreas but 
also in many other tissues as well (Schneider et al. 2005; Dahlhoff et al. 2009). 
 
Furthermore, treatment of the alloxan- and streptozotocin-diabetic rodents with 
recombinant betacellulin, appeared to have a significant impact on the improvement of 
glucose metabolism (Yamamoto et al. 2000; Li et al. 2003). Nevertheless, there is at 
least one study showing that betacellulin had no significant impact on insulin secretion 
and blood glucose reduction (Sjoholm & Kindmark 1999). 
 
Overexpression of different growth factors or their receptors is often associated with 
pathological alterations. Human BTC transgenic mice from L2 and L3 did not show any 
alterations in the body weight. Also, general conditions of these animals were 
unimpaired. In contrast, studies employing mouse models with an ubiquitously 
overexpression of BTC demonstrated an early postnatal mortality rate and reduced body 
weight gain (Schneider et al. 2005). A retarded growth has been also reported in mice 
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overexpressing other EGFR ligands such as TGFA (Sandgren et al. 1993) or EGF (Chan 
& Wong 2000; Wong et al. 2000). Moreover, in contrast to betacellulin, the elevated 
expression of epithelial growth factors like TGFA (Sandgren et al. 1990) and HB-EGF 
(Means et al. 2003) has been shown to cause epithelial metaplasia, pancreatic 
hyperplasia and fibrosis in transgenic mice (Sandgren et al. 1990; Means et al. 2003). 
Furthermore, even though betacellulin is known for its mitogenic activity (Shing et al. 
1993; Kim et al. 2003), histological analysis of different tissues from PIP-hBTC mice 
did not detect any alterations pointing to tumor development. The life-span of the 
transgenic animals remained unimpaired. 
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5 SUMMARY 
 
 
Analysis of a new transgenic mouse model with β-cell specific overexpression of 
human betacellulin 
 
In the present study, a new transgenic mouse model was generated in order to evaluate 
whether the full 5’ untranslated region (UTR) of the porcine insulin gene was able to 
confer expression of a transgene robustly and specifically in the pancreatic β-cells. 
An expression cassette containing 1500 base pairs of the 5’ UTR porcine insulin gene 
promoter and 3’ UTR of the bovine growth hormone gene was designed to permit easy 
exchange of the sequences to be expressed. The functionality of the cassette was 
verified by employing a cDNA encoding human betacellulin, a growth factor known to 
affect structural and functional parameters of β-cells. 
The functionality of the PIP-hBTC construct was initially evaluated by conducting in 
vitro experiments. Transfection of different cell types with the PIP-hBTC vector, 
followed by Western blot analysis of the isolated proteins, showed the presence of 
human betacellulin solely in the mouse MIN-6 β-cell line. 
Next, two transgenic mouse lines (L2 and L3) were generated by pronuclear DNA 
microinjection. For evaluation of expression specificity, tissue samples of the liver, gut, 
kidney, muscle and pancreatic islets were removed from the transgenic and control 
mice, and analysed using reverse transcription PCR and immunhistochemistry. These 
investigations demonstrated the presence of human betacellulin only within the 
endocrine pancreas of the transgenic animals with concomitant absence of transgene 
expression in any other organ or in tissues of control littermates. 
Considering the reported ectopic activity of the rat insulin promoter in some brain areas 
of transgenic mice, the potential action of the porcine insulin promoter in different parts 
of the brain was analysed using reverse transcription PCR and immunhistochemistry. 
Transcripts for human betacellulin were never detected in any of the examined regions 
of the ventral brain. 
Employment of multicolour immunofluorescence and confocal laser scanning 
microscopy confirmed expression of human betacellulin solely by insulin producing 
cells of the transgenic mice, confirming the β-cell specificity of the expression. 
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PIP-hBTC transgenic mice from both lines developed normally, were fertile and did not 
exhibit any abnormalities. Also, histological analysis of the pancreas and other organs 
removed from older individuals did not reveal any pathological alterations. 
Confirming the known insulinotropic effects of betacellulin, transgenic mice 
demonstrated an improved glucose metabolism: during intraperitoneal glucose tolerance 
test, PIP-hBTC mice cleared glucose significantly faster as compared with their control 
littermates. 
Taking together, the newly designed expression cassette, containing 1500 base pairs of 
the 5’UTR of the porcine insulin promoter, drove the expression of the transgene 
robustly and specifically to β-cells, in vitro and in transgenic mice. It also represents a 
significant improvement over available expression systems due to easy exchange of the 
sequences to be expressed. Moreover, the possibility of eliciting a β-cell-specific 
expression of gene products in transgenic large animal models without unwanted 
expression in other tissues could become useful for future studies in diabetes research. 
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6 ZUSAMMENFASSUNG 
 
 
Untersuchung eines neuen transgenen Mausmodells mit β-Zell-spezifischer 
Überexpression des humanen Betacellulins 
 
Ziel dieser Studie war die Erstellung eines transgenen Mausmodells zur Überprüfung 
der Fähigkeit des 5’ untranslatierten Bereich (UTR) des Schweineinsulin-Genes, eine 
stabile und spezifische Expression des Transgens in pankreatischen β-Zellen 
hervorzurufen. 
Das Expressionskonstrukt besteht aus 1500 Basenpaaren des 5’ UTR des 
Schweineinsulin-Promotors (Porcine Insulin Promoter, PIP) und dem 3’ UTR des 
Rinderwachstumshormon-Genes (bovine Growth Hormone, bGH). Der Aufbau des 
Konstruktes ermöglicht eine einfache Verwendung für Sequenzen unterschiedlicher 
Transgene. Die Funktionalität der Kassette konnte durch den Einsatz der für das 
humane Betacellulin (hBTC) kodierende cDNA nachgewiesen werden. Betacellulin ist 
ein Wachstumsfaktor der die funktionellen und strukturellen Parameter der β-Zellen 
beeinflussen kann. 
Die spezifische Expression des Konstruktes wurde zunächst mit Hilfe von in vitro 
Experimenten überprüft. Verschiedene Zelltypen wurden mit dem PIP-hBTC Vektor 
transfiziert. Der Expressionsnachweis von BTC in den Zelllysaten erfolgte mittels 
Western-Blot-Analysen. Das hBTC-Protein konnte ausschließlich in der MIN6-
Insulinoma Zelllinie gefunden werden. 
Anschließend wurden zwei transgene Mauslinien (L2 und L3) durch 
DNA-Mikroinjektionen in die Vorkerne befruchteter Eizellen erstellt. Um die 
Expressionsspezifität in vivo beurteilen zu können, wurden Gewebeproben aus Leber, 
Darm, Niere, Muskel und isolierten pankreatischen Inseln von transgenen Mäusen und 
Kontrolltieren (Wurfgeschwister) entnommen und sowohl durch die Reverse 
Transkriptase-Polymerase-Kettenreaktion (RT-PCR) als auch durch 
immunhistochemische Verfahren untersucht. Das humane BTC konnte hierbei nur 
innerhalb des endokrinen Pankreas der transgenen Mäuse nachgewiesen werden. 
Da es Untersuchungen gibt, in denen eine zusätzliche Aktivität des Ratteninsulin-
Promotors in einigen Gehirnbereichen transgener Tiere festgestellt worden sind, wurde 
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eine potentielle Aktivität des Schweineinsulin-Promotors im Gehirn der hBTC-
transgenen Mäuse überprüft. Die Ergebnisse der RT-PCR und der Immunhistochemie 
haben keinerlei Expression des hBTC in den Gehirnen der transgenen Tiere gezeigt. 
Zur Überprüfung der β-Zell-Expressionsspezifität wurde eine konfokale Mehrfarb-
Immunfluoreszenzmikroskopie durchgeführt. Hierbei wurde das humane Betacellulin 
ausschließlich in den Insulin-produzierenden Zellen nachgewiesen. 
Obwohl mehrere Studien über mitogene Eigenschaften des humanen BTC berichten, 
konnten wir keine Entwicklungsstörungen und Fertilitätsprobleme in 
PIP-hBTC-Mäusen beobachten. Außerdem ergaben die histologischen Analysen der 
Pankreatiden und anderen Organen der älteren Tiere keine pathologischen 
Veränderungen. 
Die Blutglukose-senkende Wirkung von Betacellulin wurde auch in dieser Studie 
bestätigt: In intraperitonealen Glukose-Toleranz-Tests zeigten die PIP-hBTC-transgenen 
Tiere eine signifikant schnellere Senkung des Blutglukosespiegels im Vergleich zu 
ihren Kontrollgeschwistern. 
Zusammenfassend kann gesagt werden, dass das für diese Arbeit generierte Konstrukt 
mit seinen 1500 Basenpaaren des 5’UTR des Schweineinsulin-Promotors zu einer 
stabilen und spezifischen Expression eines Transgens ausschließlich in den β-Zellen des 
Pankreas führt. Ein weiterer Vorteil dieses Konstrukts ist der einfache Austausch der 
zur Expression vorgesehenen Sequenz. Darüber hinaus, bietet eine β-Zell-spezifische 
Überexpression (ohne ungewollte Expression in anderen Organen) eines gewünschten 
Genprodukts die Möglichkeit in Großtiermodellen beispielsweise Studien über neue 
Therapiemethoden, wie Xenotransplantationen, gegen Diabetes Mellitus durchzuführen. 
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